Navigation Links
Cure HIV Reaches Out to Foundation Community to Fund LiSAVIOR
Date:4/1/2008

HILTON HEAD ISLAND, S.C., April 1 /PRNewswire/ -- Dr. Roger Kenneth Hershline, PhD, MD, the CEO of Global Humanceuticals, Inc. and founder and chairman of the not-for-profit public charity CureHIV.us, announces today that he is reaching out to the funder community, including funding initiatives such as the Grand Challenges in Global Health initiative. The monies would be used to begin clinical studies of a new drug and treatment method, LiSAVIOR.

This unique new drug is also known as compound NIAID #11039 and has received a patent from the United States with patent number 6,821,958 on November 23, 2004. Also, the World International Patent Organization published the International Application Number as PCT/US2005/039528 on November 5, 2006.

Dr. Hershline hosted Session V at the World AIDS Day Conference in China from December 1 to December 3, 2006, to initially present LiSAVIOR.

The proposed roadblock to cure HIV is that current drug and vaccination treatments do not treat the growth of HIV in the gastrointestinal tract. HIV virus multiplies and mutates in the gastrointestinal tract and then is reabsorbed into the blood. This process is known to occur when HIV infection results from the use of contaminated needles or during sexual intercourse. The gastrointestinal tract is comprised of the mouth and its structures, the pharynx, the esophagus, the stomach, the small intestines, the large intestines and the anus.

The proposed solution to overcome this roadblock is the oral clinical use of LiSAVIOR, a drug that is an early stage HIV life cycle inhibitor. LiSAVIOR blocks not only viral entry into cells but also cell-to-cell transfer of the virus. LiSAVIOR is proposed to be used alone or with any known HIV drug and vaccine therapy.

Pre-clinical efficacy testing of LiSAVIOR has shown that the effective concentration of LiSAVIOR is found to be equivalent to diluting a 1% solution of LiSAVIOR one million times. LiSAVIOR is a dry, palatable, non-toxic powder that is stable at room temperature and humidity.

"I am thinking in terms of problem solving. Traditional commercial drug design and projects funding from the NIH has completely ignored this approach to date," stated Dr. Hershline. "I think we have to talk in terms of a cure for HIV. I want to cure HIV and that is why my foundation is called CureHIV.us," concluded Dr. Hershline.

Dr. Hershline is hopeful that the foundation community, including the Grand Challenges in Global Health initiative, looks into the work and progress that he has made towards solving this problem and fills the gap in funding.

Dr. Hershline has a doctorate degree in drug design and a medical degree. Pre-clinical development of LiSAVIOR has been twenty years in the making. Despite the critical need for such a unique and potentially lifesaving invention, LiSAVIOR remains completely un-funded.

Interested parties can contact Dr. Roger Kenneth Hershline, PhD, MD, thru CureHIV.us Headquarters by email: Roger@CureHIV.us, mail: P.O. Box 23467, Hilton Head Is., SC, 29925, fax: +1-843-342-5924, phone: +1-843-342-5900. Direct to Dr. Hershline: +1-843-683-3683.

Web site: http://www.curehiv.us

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE CureHIV.us
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
2. Luminex Corporation Reaches Settlement With Rules Based Medicine, Inc.
3. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
4. Genmab Reaches Milestones in Ofatumumab Collaboration
5. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
6. Fralex reaches 100th patient milestone in fibromyalgia study
7. Life Sciences Industry Reaches Crossroad Say Noted Pillsbury Attorneys
8. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007
9. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
10. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
11. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... ... specialists DST Diagnostische Systeme & Technologien GmbH, thereby expanding its product portfolio to ... from hay fever, urticaria, asthma, atopic eczema or a food allergy. Allergies are ...
(Date:6/22/2017)... ... , ... The first human cell line HeLa, established in 1951, has entered ... of human cell lines with HeLa cells were published. Until recently, cross-contamination and misidentification ... is associated with dramatic consequences for research. , In this educational webinar, which ...
(Date:6/20/2017)... ... June 20, 2017 , ... Biologist Dawn Maslar MS has found a biomarker ... Men Chase, Women Choose: The Neuroscience of Meeting, Dating, Losing Your Mind, and Finding ... men. ”The logical next step, in my estimation, was to scientifically track the evidence ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... Do More ... the transition from being a trusted supplier in the weighing industry, to extending its ... extractions, ELISA essays, enzyme reactions, immunoassays, hybridizations and more, allowing for its customers ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
Breaking Biology News(10 mins):